Chelisa Cardinez

Chelisa Cardinez

Auto-generated profile, based on publicly available information

Chelisa Cardinez

Centre for Personalised Immunology, Australian National University, Canberra, Australia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2018 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
CCChelisa Cardinez
Chelisa Cardinez
BMBahar Miraghazadeh
Bahar Miraghazadeh
KTKay Tanita
Kay Tanita
ESElizabeth da Silva
Elizabeth da Silva
AHAkihiro Hoshino
Akihiro Hoshino
MCMatthew C. Cook
Matthew C. Cook
Genetic mutations account for many devastating early onset immune deficiencies. In contrast, less severe and later onset immune diseases, including in patients with no prior family history, remain poorly understood. Whole exome sequencing in two cohorts of such patients identified a novel heterozygous de novo IKBKB missense mutation (c.607G>A) in two separate kindreds in whom probands presented with immune dysregulation, combined T and B cell deficiency, inflammation, and epithelial defects. IKBKB encodes IKK2, which activates NF-κB signaling. IKK2V203I results in enhanced NF-κB signaling, as well as T and B cell functional defects. IKK2V203 is a highly conserved residue, and to prove causation, we generated an accurate mouse model by introducing the precise orthologous codon change in Ikbkb using CRISPR/Cas9. Mice and humans carrying this missense mutation exhibit remarkably similar cellular and biochemical phenotypes. Accurate mouse models engineered by CRISPR/Cas9 can help characterize novel syndromes arising from de novo germline mutations and yield insight into pathogenesis.